Single-fragment antibody VEGF inhibitor meets primary endpoint of non-inferiority

A humanized single-chain antibody fragment VEGF inhibitor to treat neovascular age-related macular degeneration was found to be non-inferior to ranibizumab intravitreal injections, according to a phase 2 multicenter study.The manufacturing of the single-fragment antibody RTH258 (formerly ESBA1008) is a collaborative venture between Alcon and Novartis.